Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2 vs 3 Doses of 9-Valent HPV Vaccine in Women 27-45 Years Old
NCT05672927Phase 4Recruiting
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Jan 2023
- Primary completion
- Aug 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by The University of Texas Medical Branch at Galveston. Started Jan 2023; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05672927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672927.